Cargando…
Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
OBJECTIVES: Subcutaneous tumour necrosis factor alpha TNFαinhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable fact...
Autores principales: | Bhoi, Peter, Bessette, Louis, Bell, Mary J, Tkaczyk, Cathy, Nantel, Francois, Maslova, Karina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623530/ https://www.ncbi.nlm.nih.gov/pubmed/28928177 http://dx.doi.org/10.1136/bmjopen-2017-015872 |
Ejemplares similares
-
Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry
por: Rahman, Proton, et al.
Publicado: (2017) -
Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020) -
Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study
por: Alvarez-Madrazo, Samantha, et al.
Publicado: (2019) -
Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases
por: Silvagni, Ettore, et al.
Publicado: (2018) -
The Efficacy and Safety of Subcutaneous Ixekizumab for the Treatment of Axial Spondylarthritis: A Systematic Review and Meta-Analysis
por: Alzahrani, Ziyad, et al.
Publicado: (2023)